(NASDAQ: RPRX) Royalty Pharma's forecast annual revenue growth rate of 20.41% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 130.27%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.57%.
Royalty Pharma's revenue in 2025 is $2,263,845,000.On average, 2 Wall Street analysts forecast RPRX's revenue for 2025 to be $1,715,465,340,753, with the lowest RPRX revenue forecast at $1,687,896,451,402, and the highest RPRX revenue forecast at $1,743,034,792,343. On average, 2 Wall Street analysts forecast RPRX's revenue for 2026 to be $1,831,322,257,304, with the lowest RPRX revenue forecast at $1,779,067,084,462, and the highest RPRX revenue forecast at $1,883,577,992,385.
In 2027, RPRX is forecast to generate $1,989,660,361,859 in revenue, with the lowest revenue forecast at $1,968,333,463,976 and the highest revenue forecast at $2,010,987,259,743.